文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性低氧血症初始治疗中经鼻高流量氧疗与无创通气的比较:倾向性评分匹配研究

High-Flow Nasal Cannula Versus Noninvasive Ventilation as Initial Treatment in Acute Hypoxia: A Propensity Score-Matched Study.
PubMed 文献 · Crit Care Explor · 2024-05-08
一句话结论急性低氧性呼吸衰竭患者初始使用NIV较HFNC与更低的28天死亡率相关(16.5% vs 23.4%),复合主要肺部不良事件win ratio支持NIV(1.38)。

该回顾性队列研究纳入2018年1月至2022年12月密歇根大学成人急诊科24小时内接受HFNC或NIV治疗的急性低氧性呼吸衰竭患者1154例,其中726例(62.9%)接受HFNC、428例(37.1%)接受NIV,按接受NIV的倾向性评分1:1匹配668例(57.9%)。匹配后NIV组较HFNC组28天死亡率更低(16.5% vs 23.4%,p=0.033),无创治疗时间更短(中位7.5小时 vs 13.5小时,p<0.001),无呼吸机天数无差异(中位28[26,28] vs 28[10.5,28],p=0.199)。复合主要肺部不良事件win ratio支持NIV(1.38;95%CI 1.15-1.65;p<0.001)。作者认为这些发现强调需要随机对照试验进一步理解无创呼吸支持策略的影响。

要点

  • 匹配后NIV组28天死亡率16.5%,低于HFNC组的23.4%(p=0.033)。
  • 匹配后NIV组无创呼吸支持时间中位7.5小时,短于HFNC组的13.5小时(p<0.001)。
  • 匹配后两组无呼吸机天数无差异:NIV组中位28[26,28] vs HFNC组28[10.5,28](p=0.199)。
  • 复合主要肺部不良事件win ratio为1.38(95%CI 1.15-1.65;p<0.001),支持NIV。
  • 作者认为这些发现强调需要随机对照试验进一步理解无创呼吸支持策略的影响。

适用人群与场景

  • 2018年1月至2022年12月到达密歇根大学成人急诊科24小时内接受HFNC或NIV治疗的急性低氧性呼吸衰竭患者。
  • 急诊科就诊的低氧血症患者常为混合或原因不明的呼吸衰竭,其最佳治疗不明确,HFNC与NIV均在使用。

研究设计与关键结果

  • 研究设计:回顾性队列研究,纳入1154例患者,其中726例(62.9%)接受HFNC、428例(37.1%)接受NIV,按接受NIV的倾向性评分1:1匹配668例(57.9%)。
  • 主要终点:复合主要肺部不良事件(28天死亡率、无呼吸机天数、无创呼吸支持小时数)以win ratio计算,匹配后win ratio支持NIV(1.38;95%CI 1.15-1.65;p<0.001)。
  • 匹配后NIV组 vs HFNC组28天死亡率:16.5% vs 23.4%(p=0.033)。
  • 匹配后NIV组 vs HFNC组无创呼吸支持时间:中位7.5小时 vs 13.5小时(p<0.001)。
  • 匹配后NIV组 vs HFNC组无呼吸机天数:中位28[26,28] vs 28[10.5,28](p=0.199),无差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,采用倾向性评分1:1匹配。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急诊科急性低氧性呼吸衰竭患者中,初始治疗使用NIV较HFNC与更低的28天死亡率和更少的复合主要肺部不良事件相关(win ratio 1.38;95%CI 1.15-1.65;p<0.001)。
  • 作者认为这些发现强调需要随机对照试验进一步理解无创呼吸支持策略的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients presenting to the emergency department (ED) with hypoxemia often have mixed or uncertain causes of respiratory failure. The optimal treatment for such patients is unclear. Both high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) are used.

OBJECTIVES: We sought to compare the effectiveness of initial treatment with HFNC versus NIV for acute hypoxemic respiratory failure.

DESIGN SETTING AND PARTICIPANTS: We conducted a retrospective cohort study of patients with acute hypoxemic respiratory failure treated with HFNC or NIV within 24 hours of arrival to the University of Michigan adult ED from January 2018 to December 2022. We matched patients 1:1 using a propensity score for odds of receiving NIV.

MAIN OUTCOMES AND MEASURES: The primary outcome was major adverse pulmonary events (28-d mortality, ventilator-free days, noninvasive respiratory support hours) calculated using a win ratio.

RESULTS: A total of 1154 patients were included. Seven hundred twenty-six (62.9%) received HFNC and 428 (37.1%) received NIV. We propensity score matched 668 of 1154 (57.9%) patients. Patients on NIV versus HFNC had lower 28-day mortality (16.5% vs. 23.4%, p = 0.033) and required noninvasive treatment for fewer hours (median 7.5 vs. 13.5, p < 0.001), but had no difference in ventilator-free days (median [interquartile range]: 28 [26, 28] vs. 28 [10.5, 28], p = 0.199). Win ratio for composite major adverse pulmonary events favored NIV (1.38; 95% CI, 1.15-1.65; p < 0.001).

CONCLUSIONS AND RELEVANCE: In this observational study of patients with acute hypoxemic respiratory failure, initial treatment with NIV compared with HFNC was associated with lower mortality and fewer composite major pulmonary adverse events calculated using a win ratio. These findings underscore the need for randomized controlled trials to further understand the impact of noninvasive respiratory support strategies.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Munroe ES, Prevalska I, Hyer M, et al. High-Flow Nasal Cannula Versus Noninvasive Ventilation as Initial Treatment in Acute Hypoxia: A Propensity Score-Matched Study. Crit Care Explor. 2024. PMID: 38725442. doi:10.1097/CCE.0000000000001092

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。